KR20170129823A - 브리모니딘 및 티몰롤의 고정된 용량 조합 - Google Patents

브리모니딘 및 티몰롤의 고정된 용량 조합 Download PDF

Info

Publication number
KR20170129823A
KR20170129823A KR1020177029678A KR20177029678A KR20170129823A KR 20170129823 A KR20170129823 A KR 20170129823A KR 1020177029678 A KR1020177029678 A KR 1020177029678A KR 20177029678 A KR20177029678 A KR 20177029678A KR 20170129823 A KR20170129823 A KR 20170129823A
Authority
KR
South Korea
Prior art keywords
composition
tartrate
maleate
bimonidine
brimonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177029678A
Other languages
English (en)
Korean (ko)
Inventor
짐 자오
친-밍 창
아누라다 브이. 고어
리차드 에스. 그레이엄
알. 스콧 조단
세샤 네르바난
체탄 피. 푸자라
지에 센
케빈 에스. 워너
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20170129823A publication Critical patent/KR20170129823A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020177029678A 2015-03-19 2016-03-17 브리모니딘 및 티몰롤의 고정된 용량 조합 Ceased KR20170129823A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135320P 2015-03-19 2015-03-19
US62/135,320 2015-03-19
PCT/US2016/022874 WO2016149498A1 (en) 2015-03-19 2016-03-17 Fixed dose combination of bromonidine and timolol

Publications (1)

Publication Number Publication Date
KR20170129823A true KR20170129823A (ko) 2017-11-27

Family

ID=55640942

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177029678A Ceased KR20170129823A (ko) 2015-03-19 2016-03-17 브리모니딘 및 티몰롤의 고정된 용량 조합

Country Status (9)

Country Link
US (3) US20180078500A1 (cg-RX-API-DMAC10.html)
EP (2) EP4420726A3 (cg-RX-API-DMAC10.html)
JP (4) JP7199146B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170129823A (cg-RX-API-DMAC10.html)
CN (1) CN107427460A (cg-RX-API-DMAC10.html)
AU (3) AU2016233125A1 (cg-RX-API-DMAC10.html)
CA (1) CA2977825A1 (cg-RX-API-DMAC10.html)
HK (1) HK1246689A1 (cg-RX-API-DMAC10.html)
WO (1) WO2016149498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
WO2019112030A1 (ja) * 2017-12-08 2019-06-13 千寿製薬株式会社 水溶性高分子を含む水性液剤
JP7378959B2 (ja) * 2018-05-11 2023-11-14 千寿製薬株式会社 眼科用組成物
US20210220515A1 (en) * 2018-05-25 2021-07-22 Eyebright Medical Technology (Beijing) Co., Ltd. Viscoelastic agent material
JP7630944B2 (ja) * 2019-09-12 2025-02-18 千寿製薬株式会社 ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
WO2023086878A1 (en) 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects
CN115671037A (zh) * 2022-11-21 2023-02-03 山东诺明康药物研究院有限公司 一种溴莫尼定噻吗洛尔pH敏感型原位凝胶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
EP1365811A2 (en) * 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20070238732A1 (en) 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
BR112012017319A2 (pt) 2009-12-22 2016-04-19 Allergan Inc composições e métodos para abaixar a pressão intraocular
PT2598119T (pt) * 2010-07-29 2018-12-17 Allergan Inc Soluções de brimonidina e timolol isentas de conservantes
CN103501804A (zh) 2010-12-21 2014-01-08 雷科制药公司 眼泪替代物
EP3086776B1 (en) * 2013-12-24 2020-06-17 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
US20160331746A1 (en) * 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Also Published As

Publication number Publication date
JP2021102626A (ja) 2021-07-15
JP2025100564A (ja) 2025-07-03
US20250387325A1 (en) 2025-12-25
JP2018508545A (ja) 2018-03-29
US20220370346A1 (en) 2022-11-24
EP4420726A3 (en) 2024-11-13
WO2016149498A1 (en) 2016-09-22
AU2021203665A1 (en) 2021-09-02
EP4420726A2 (en) 2024-08-28
HK1246689A1 (zh) 2018-09-14
JP7199146B2 (ja) 2023-01-05
AU2016233125A1 (en) 2017-09-14
CN107427460A (zh) 2017-12-01
JP2023086773A (ja) 2023-06-22
EP3270892A1 (en) 2018-01-24
US20180078500A1 (en) 2018-03-22
AU2023208076A1 (en) 2023-08-10
EP3270892B1 (en) 2024-04-10
CA2977825A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
US20250387325A1 (en) Fixed dose combination of brimonidine and timolol
US10792288B2 (en) Preservative free brimonidine and timolol solutions
JP7429681B2 (ja) ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP2021102626A5 (cg-RX-API-DMAC10.html)
US6191126B1 (en) Topical use of κ opioid agonists to treat ocular pain
WO2024028815A1 (en) Ophthalmic composition comprising an anti-allergen and a redness reduction agent
KR102901189B1 (ko) 피리딜아미노아세트산 화합물을 함유하는 의약 제제
JP7247278B2 (ja) 水性医薬組成物
TW202245810A (zh) 散光之治療
WO2021210646A1 (ja) エピナスチン又はその塩を含有する水性組成物
AU2014240453A1 (en) Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
KR20100032018A (ko) 항히스타민제를 포함하는 점안용 조성물
EP4565206A1 (en) Ophthalmic composition comprising pilocarpine and a redness reduction agent
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
HK40004045A (en) Preservative free brimonidine and timolol solutions
HK1020867B (en) The topical use of kappa opioid agonists to treat ocular pain

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210311

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230221

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230830

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230221

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I